Home › Companies › Krystal Biotech, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Krystal Biotech, Inc.’s Form 8-K, filed May 20, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 15, 2026: 5 items on Krystal Biotech, Inc.’s Form 8-K, filed May 20, 2026: 2 approved · 3 passed (calculated).
Notable dissent: 2 directors (16.0%, 11.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Krystal Biotech, Inc. in the interactive database Compare manager voting policies
These tallies are Krystal Biotech, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 20, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Krish S. Krishnan | 23,802,920 | -- | -- | 3,079,194 | 1,581,473 | 89% | Passed (calculated) | — |
| Elect Director: Christopher Mason | 22,581,854 | -- | -- | 4,300,260 | 1,581,473 | 84% | Passed (calculated) | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm | 28,443,155 | 15,434 | 4,998 | -- | -- | 99.9% | Approved | — |
| 3. Non-Binding, Advisory Vote on Named Executive Officer Compensation | 25,679,318 | 1,195,788 | 7,008 | -- | 1,581,473 | 96% | Approved | — |
| 4. Non-Employee Director Compensation Policy The Company's unaffiliated stockholders (i.e., excluding the members of the Company's board of directors and the defendants in the litigation entitled Corbin v | 21,374,021 | 2,349,550 | 3,158,543 | -- | 1,581,473 | 90% | Passed (calculated) | — |
Source: Krystal Biotech, Inc., Form 8-K, filed with the SEC on May 20, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
373 asset managers disclosed a vote on at least one Krystal Biotech, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Christopher Mason
Krystal Biotech, Inc.’s own tally for this item (“Elect Director: Christopher Mason”): 22,581,854 for, 4,300,260 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 106 asset managers below reported 11,055,090 for, 1,588,277 withheld, 117,825 abstained, 18,548 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,684,367 | 0 | 15 | 0 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 755,181 | 0 | 0 | 0 | For |
| State Street | 1,684 | 0 | 0 | 694,945 | Withhold |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 349,271 | Withhold |
| Charles Schwab | 211,339 | 0 | 0 | 0 | For |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 150,000 | 0 | 0 | 0 | For |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 0 | 0 | 0 | 91,520 | Withhold |
| Voya | 67,317 | 0 | 0 | 0 | For |
| Equitable | 43,274 | 0 | 0 | 20,060 | Mixed |
| NEW ECONOMY FUND | 62,845 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 58,432 | 0 | Abstain |
| Dimensional | 0 | 0 | 0 | 51,803 | Withhold |
| Janus Detroit Street Trust | 0 | 0 | 0 | 48,180 | Withhold |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 6,160 | 0 | 29,481 | 0 | Mixed |
| Victory Capital | 0 | 0 | 0 | 34,820 | Withhold |
| Lincoln Financial | 1,261 | 0 | 0 | 27,691 | Withhold |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Showing the 25 largest of 106 asset managers. All 106 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Krish S. Krishnan
Krystal Biotech, Inc.’s own tally for this item (“Elect Director: Krish S. Krishnan”): 23,802,920 for, 3,079,194 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 106 asset managers below reported 11,716,487 for, 926,885 withheld, 117,820 abstained, 18,548 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,680,656 | 0 | 10 | 3,715 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 755,181 | 0 | 0 | 0 | For |
| State Street | 695,716 | 0 | 0 | 913 | For |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 349,271 | Withhold |
| Charles Schwab | 211,339 | 0 | 0 | 0 | For |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 150,000 | 0 | 0 | 0 | For |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 0 | 0 | 0 | 91,520 | Withhold |
| Voya | 0 | 0 | 0 | 67,317 | Withhold |
| Equitable | 43,274 | 0 | 0 | 20,060 | Mixed |
| NEW ECONOMY FUND | 62,845 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 58,432 | 0 | Abstain |
| Dimensional | 0 | 0 | 0 | 51,803 | Withhold |
| Janus Detroit Street Trust | 0 | 0 | 0 | 48,180 | Withhold |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 6,160 | 0 | 29,481 | 0 | Mixed |
| Victory Capital | 0 | 0 | 0 | 34,820 | Withhold |
| Lincoln Financial | 18,007 | 0 | 0 | 10,945 | Mixed |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Showing the 25 largest of 106 asset managers. All 106 are in the interactive database (link above).
Combines 11 wordings of this item as funds reported it.
96% Approved · of votes cast
Prior year: 94.1% for (May 16, 2025 meeting) ▲ 1.5 pts
Description as filed by funds: Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.
Krystal Biotech, Inc.’s own tally for this item (“3. Non-Binding, Advisory Vote on Named Executive Officer Compensation”): 25,679,318 for, 1,195,788 against — passed, per its Form 8-K filed May 20, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025, as disclosed in the Company's proxy sta…”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,684,379 | 3 | 0 | 0 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 0 | 755,181 | 0 | 0 | Against |
| State Street | 696,266 | 363 | 0 | 0 | For |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 349,271 | 0 | 0 | 0 | For |
| Charles Schwab | 211,339 | 0 | 0 | 0 | For |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 150,000 | 0 | 0 | 0 | For |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 91,520 | 0 | 0 | 0 | For |
| Voya | 67,317 | 0 | 0 | 0 | For |
| Equitable | 63,334 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 0 | 62,845 | 0 | 0 | Against |
| Jackson National | 58,432 | 0 | 0 | 0 | For |
| Dimensional | 51,803 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 48,180 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 35,641 | 0 | 0 | 0 | For |
| Victory Capital | 34,820 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,952 | 0 | 0 | 0 | For |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Fund voting reports, all 106 managers: 11,923,880 for, 831,534 against, 4,676 abstained, 18,548 not voted, 54 mixed. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,310,729 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 2,542,298 | 0 | 0 | 0 | For |
| State Street | 1,150,493 | 5,274 | 0 | 0 | For |
| BlackRock | 849,050 | 11,386 | 0 | 0 | For |
| Capital Group | 0 | 823,759 | 0 | 0 | Against |
| Redmile Group, LLC | 673,505 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 617,871 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 565,170 | 0 | 0 | 0 | For |
| T. Rowe Price | 510,357 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 481,307 | 0 | 0 | 0 | For |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 319,160 | 0 | 0 | 0 | For |
| Charles Schwab | 241,202 | 0 | 0 | 0 | For |
| Vanguard | 216,894 | 0 | 0 | 0 | For |
| Invesco | 201,686 | 13 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 201,001 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 175,358 | 0 | 0 | 0 | For |
| Northern Trust | 164,495 | 2,506 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 161,116 | 0 | 0 | 0 | For |
| Woodline Partners LP | 150,616 | 0 | 0 | 0 | For |
| Nuveen | 141,590 | 0 | 0 | 0 | For |
| Janus Henderson | 112,930 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 108,737 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 101,850 | 0 | 0 | 0 | For |
| Voya | 97,545 | 0 | 0 | 0 | For |
| S SQUARED TECHNOLOGY, LLC | 86,215 | 0 | 0 | 0 | For |
Institutional-manager reports, all 291 managers: 15,683,475 for, 1,101,445 against, 17 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: Approval of the Company's Non- Employee Director Compensation Policy.
Krystal Biotech, Inc.’s own tally for this item (“4. Non-Employee Director Compensation Policy The Company's unaffiliated stockholders (i.e., excluding the members of the the Company's board of directors and the defendants in the litigation entitled Corbin v”): 21,374,021 for, 2,349,550 against, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,680,646 | 3,724 | 11 | 0 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 0 | 755,181 | 0 | 0 | Against |
| State Street | 696,408 | 221 | 0 | 0 | For |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 349,271 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 211,339 | 0 | 0 | Against |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 0 | 150,000 | 0 | 0 | Against |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 91,520 | 0 | 0 | 0 | For |
| Voya | 67,317 | 0 | 0 | 0 | For |
| Equitable | 63,334 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 0 | 62,845 | 0 | 0 | Against |
| Jackson National | 58,432 | 0 | 0 | 0 | For |
| Dimensional | 51,803 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 48,180 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 35,641 | 0 | 0 | 0 | For |
| Victory Capital | 34,820 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,952 | 0 | 0 | 0 | For |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Fund voting reports, all 106 managers: 11,509,632 for, 1,250,448 against, 11 abstained, 18,548 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 481,307 | 0 | 0 | 0 | For |
| Granite Investment Partners, LLC | 18,218 | 0 | 0 | 0 | For |
| ZACKS INVESTMENT MANAGEMENT | 13,774 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 8,700 | 0 | 0 | 0 | For |
| Janney Montgomery Scott LLC | 0 | 4,369 | 0 | 0 | Against |
| Vident Advisory, LLC | 1,481 | 0 | 0 | 0 | For |
| Sound View Wealth Advisors Group, LLC | 1,392 | 0 | 0 | 0 | For |
| Royal Capital Wealth Management, LLC | 278 | 0 | 0 | 0 | For |
| L2 Asset Management, LLC | 139 | 0 | 0 | 0 | For |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 70 | 0 | 0 | 0 | For |
| Boltwood Capital Management | 58 | 0 | 0 | 0 | For |
| AUGUSTINE ASSET MANAGEMENT INC | 29 | 0 | 0 | 0 | For |
| Summit Trail Advisors, LLC | 11 | 0 | 0 | 0 | For |
| IMA Advisory Services, Inc. | 10 | 0 | 0 | 0 | For |
| Keel Point, LLC | 9 | 0 | 0 | 0 | For |
| Biltmore Family Office, LLC | 5 | 0 | 0 | 0 | For |
| Waverly Advisors, LLC | 5 | 0 | 0 | 0 | For |
| Naviter Wealth, LLC | 2 | 0 | 0 | 0 | For |
| Performance Wealth Partners, LLC | 1 | 0 | 0 | 0 | For |
| White Lighthouse Investment Management Inc. | 1 | 0 | 0 | 0 | For |
Institutional-manager reports, all 20 managers: 525,490 for, 4,369 against.
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (May 16, 2025 meeting) unchanged
Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.
Krystal Biotech, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 28,443,155 for, 15,434 against — passed, per its Form 8-K filed May 20, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 110 asset managers below reported 12,760,222 for, 10,466 against, 4,676 abstained, 18,548 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,684,382 | 0 | 0 | 0 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 755,181 | 0 | 0 | 0 | For |
| State Street | 696,629 | 0 | 0 | 0 | For |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 349,271 | 0 | 0 | 0 | For |
| Charles Schwab | 211,339 | 0 | 0 | 0 | For |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 150,000 | 0 | 0 | 0 | For |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 91,520 | 0 | 0 | 0 | For |
| Voya | 67,317 | 0 | 0 | 0 | For |
| Equitable | 63,334 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 62,845 | 0 | 0 | 0 | For |
| Jackson National | 58,432 | 0 | 0 | 0 | For |
| Dimensional | 51,803 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 48,180 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 35,641 | 0 | 0 | 0 | For |
| Victory Capital | 34,820 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,952 | 0 | 0 | 0 | For |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Showing the 25 largest of 110 asset managers. All 110 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 29,437,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 12.17% |
| 2 | Vanguard | 9.12% |
| 3 | BlackRock | 7.34% |
| 4 | Capital Group | 2.57% |
| 5 | State Street | 2.37% |
| 6 | T. Rowe Price | 1.27% |
| 7 | Manager Directed Portfolios | 1.19% |
| 8 | First Trust | 1.19% |
| 9 | Charles Schwab | 0.72% |
| 10 | Invesco | 0.64% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.64% |
| 2 | Avoro Capital Advisors LLC | 8.64% |
| 3 | State Street | 3.93% |
| 4 | BlackRock | 2.92% |
| 5 | Capital Group | 2.80% |
| 6 | Redmile Group, LLC | 2.29% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.10% |
| 8 | Hood River Capital Management LLC | 1.92% |
| 9 | T. Rowe Price | 1.73% |
| 10 | Frazier Life Sciences Management, L.P. | 1.64% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 4,373,987 | 14.86% | Form 13F, quarter ended March 31, 2026 |
| FMR LLC | 4,292,881 | 14.58% | Proxy statement (DEF 14A), table as of March 23, 2026 |
| BlackRock | 3,940,456 | 13.39% | Form 13F, quarter ended March 31, 2026 |
| Krish S. Krishnan | 3,388,283 | 11.51% | Schedule 13G, filed May 4, 2026 |
| Vanguard Group | 2,778,845 | 9.44% | Form 13F, quarter ended March 31, 2026 |
| Avoro Capital Advisors LLC | 2,565,555 | 8.72% | Proxy statement (DEF 14A), table as of March 23, 2026 |
| Suma M. Krishnan | 1,664,505 | 5.65% | Proxy statement (DEF 14A), table as of March 23, 2026 |
| State Street | 1,314,434 | 4.47% | Form 13F, quarter ended March 31, 2026 |
| T. Rowe Price | 485,074 | 1.65% | Form 13F, quarter ended March 31, 2026 |
| Dimensional Fund Advisors | 468,990 | 1.59% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 29,437,000 shares outstanding, as reported by Krystal Biotech, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Krystal Biotech, Inc.'s shareholder meeting held May 15, 2026, in the 2025-2026 proxy season, 373 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,267 separate fund positions. On the most widely held item on that ballot — Approval of the compensation of the Company's named executive officers, on a non-binding… — Krystal Biotech, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Krystal Biotech, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 20, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Krystal Biotech, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Krystal Biotech, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Krystal Biotech (KRYS) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/krystal-biotech-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.